Title : Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.

Pub. Date : 2012 Dec 5

PMID : 23223310






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 D2-like receptor (D2R) agonists are a powerful clinical option as an alternative to L-DOPA, especially in the early stages of the disease, being associated to a reduced risk of dyskinesia development. Levodopa dopamine receptor D2 Homo sapiens
2 D2R agonists also find considerable application in the advanced stages of PD, in conjunction with L-DOPA, which is used in this context at lower dosages, to delay the appearance and the extent of the motor complications. Levodopa dopamine receptor D2 Homo sapiens